Stocks
Mutual Funds
ETFs
Pro Tools
Terminal
WealthView
Pricing
Learn More
stocks
GLENMARK
GLENMARK

Glenmark Pharmaceuticals Ltd.

NSE: GLENMARK
BSE: 532296
Sector: Healthcare
Industry: Pharmaceuticals
2,223.70-41.2 (-1.82%)
8 Jul, 12:00 AM

Stock Scores

Quality Score

86.1 / 100

Value Score

25.1 / 100

Price Momentum Score

85.2 / 100

QVM Score

80.1 / 100

Key Metrics

Market Cap
62753.00
P/E (TTM)
46.08
P/B
5.97
P/S (TTM)
3.70
EV/EBITDA
32.48
CAPE (5Y)
179.41
ROE (TTM)
14.07
ROCE (TTM)
34.99
ROA (TTM)
7.58
Avg 3Y ROE
3.09
Earnings 3Y CAGR
66.09
Sales 3Y CAGR
9.34
Sales 5Y CAGR
9.19
Debt/Equity
0.00
Consensus TP
2575.00
Strong Buy %
44.44
Promoter Holding
46.65
Pledged %
0.00

Share Price

Track Glenmark Pharmaceuticals Ltd.'s current share price, historical price chart, 52-week high/low, and performance across different time periods.

1 Week returns: 2.86 %
Low
2,142.8
High
2,299.1
1 Month returns: 2.17 %
Low
2,101.0
High
2,299.1
1 Year returns: 21.48 %
Low
1,792.6
High
2,474.0
3 Year CAGR: 47.63 %
Low
661.0
High
2,474.0
5 Year CAGR: 27.90 %
Low
348.5
High
2,474.0
Note: Prices may be delayed by a few minutes. For historical calculations, prices are adjusted for splits, bonus and rights issue. Percentage change shown is absolute irrespective of the period.

Financial Snapshot

See detailed analysis

Multi-year trends for Glenmark Pharmaceuticals Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Glenmark Pharmaceuticals Ltd. Shareholding Pattern

Quarterly breakdown of Glenmark Pharmaceuticals Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Glenmark Pharmaceuticals Ltd. shares as reported to NSE and BSE.

Frequently Asked Questions

What is the current share price of Glenmark Pharmaceuticals Ltd.?
The current share price of Glenmark Pharmaceuticals Ltd. is ₹ 2,223.70 as of 8 Jul 2026.
What is the market capitalisation of Glenmark Pharmaceuticals Ltd.?
The market capitalisation of Glenmark Pharmaceuticals Ltd. stands at ₹ 62,753.00 Cr.
What is the PE ratio of Glenmark Pharmaceuticals Ltd.?
The Price-to-Earnings (PE) ratio of Glenmark Pharmaceuticals Ltd. is 46.08 as of the latest trailing twelve months data.
What is the ROE and ROCE of Glenmark Pharmaceuticals Ltd.?
Glenmark Pharmaceuticals Ltd. has a Return on Equity (ROE) of 14.07% and a Return on Capital Employed (ROCE) of 34.99% as per the latest financial reports.
What is the 52-week high and low of Glenmark Pharmaceuticals Ltd.?
The 52-week high of Glenmark Pharmaceuticals Ltd. is - and the 52-week low is -.
What is the dividend yield of Glenmark Pharmaceuticals Ltd.?
The dividend yield of Glenmark Pharmaceuticals Ltd. is 0.22% based on the current market price.
What is the FII and DII holding in Glenmark Pharmaceuticals Ltd.?
Foreign Institutional Investors (FII) hold 20.35%, Domestic Institutional Investors (DII) hold 17.86% and retail/public investors hold 11.56% of Glenmark Pharmaceuticals Ltd. shares.
What sector does Glenmark Pharmaceuticals Ltd. belong to?
Glenmark Pharmaceuticals Ltd. operates in the Healthcare sector. 77.78% of analysts have a Buy or Strong Buy rating on Glenmark Pharmaceuticals Ltd. with a consensus target price of ₹ 2,575.00, implying 15.8% upside from current levels.
What is the beta of Glenmark Pharmaceuticals Ltd.?
The beta of Glenmark Pharmaceuticals Ltd. is 0.71, indicating its price volatility relative to the broader market. Over the past 1 year, Glenmark Pharmaceuticals Ltd. has delivered an absolute return of 26.79%.
What is the RSI of Glenmark Pharmaceuticals Ltd.?
The 14-day Relative Strength Index (RSI) of Glenmark Pharmaceuticals Ltd. is 51.47, placing it in the neutral zone. An RSI above 70 is considered overbought and below 30 is considered oversold.